康芝药业(300086)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300086 康芝药业

未开盘 11-11 09:30:00

{"stockData":{"symbol":"300086","market":"SZ","secType":"STK","nameCN":"康芝药业","latestPrice":4.86,"timestamp":1794359145000,"preClose":4.86,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":441000000,"shares":455000000,"eps":-0.46,"marketStatus":"未开盘","change":0,"latestTime":"11-11 09:30:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.46,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794360600000},"marketStatusCode":0,"adr":0,"adjPreClose":4.86,"symbolType":"stock","openAndCloseTimeList":[[1794360600000,1794367800000],[1794373200000,1794380400000]],"highLimit":5.35,"lowLimit":4.37,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":455124411,"isCdr":false,"pbRate":2.68,"roa":"--","roe":"--","epsLYR":-0.5057,"committee":0,"marketValue":2212000000,"turnoverRate":0,"status":2,"floatMarketCap":2142000000},"requestUrl":"/m/hq/s/300086","defaultTab":"news","newsList":[{"id":"2678111117","title":"股市必读：康芝药业新发布《2026年三季度报告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2678111117","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678111117?lang=zh_cn&edition=full","pubTime":"2026-10-27 04:44","pubTimestamp":1793047451,"startTime":"0","endTime":"0","summary":"截至2026年10月26日收盘，康芝药业报收于4.96元，上涨0.0%，换手率2.69%，成交量11.87万手，成交额5896.61万元。公司公告汇总：康芝药业2026年三季度营业收入同比下降45.75%，归母净利润为-4302.47万元，同比减少1.16%；前三季度累计归母净利润为-7579.12万元，同比减少21.55%。年初至报告期末营业收入为195,849,316.05元，同比下降39.99%；归属于上市公司股东的净利润为-75,791,195.73元，同比减少21.55%。总资产为1,667,085,432.44元，较上年度末下降6.92%；归属于上市公司股东的所有者权益为823,875,799.26元，较上年度末下降8.43%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700006286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","BK0042","300086","BK0048"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678187975","title":"图解康芝药业三季报：第三季度单季净利润同比下降1.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678187975","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678187975?lang=zh_cn&edition=full","pubTime":"2026-10-25 16:51","pubTimestamp":1792918297,"startTime":"0","endTime":"0","summary":"证券之星消息，康芝药业2026年三季报显示，前三季度公司主营收入1.96亿元，同比下降39.99%；归母净利润-7579.12万元，同比上升21.55%；扣非净利润-8467.44万元，同比上升14.15%；其中2026年第三季度，公司单季度主营收入5096.15万元，同比下降45.75%；单季度归母净利润-4302.47万元，同比下降1.16%；单季度扣非净利润-4324.37万元，同比下降1.45%；负债率49.36%，财务费用1318.08万元，毛利率52.02%。财报数据概要请见下图:本文数据来源于康芝药业2026年三季报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102500004459.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300086"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668041942","title":"康芝药业最新公告：因公司涉嫌信息披露违法违规收到证监会立案告知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2668041942","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668041942?lang=zh_cn&edition=full","pubTime":"2026-09-18 18:09","pubTimestamp":1789726187,"startTime":"0","endTime":"0","summary":"康芝药业(300086.SZ)公告称，公司收到证监会下发的《立案告知书》，因涉嫌信息披露违法违规，证监会决定对公司立案。截至公告披露日，公司生产经营活动正常开展，上述事项不会对正常生产经营产生重大影响。立案调查期间，公司将积极配合证监会工作，并履行信息披露义务。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091800028593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300086","BK0070","BK0042","BK0048","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667647610","title":"康芝药业：公司目前未触及财务类退市风险警示情形","url":"https://stock-news.laohu8.com/highlight/detail?id=2667647610","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667647610?lang=zh_cn&edition=full","pubTime":"2026-09-15 20:51","pubTimestamp":1789476717,"startTime":"0","endTime":"0","summary":"证券之星消息，康芝药业(300086)09月15日在投资者关系平台上答复投资者关心的问题。投资者提问：公司连续三年亏损，金额巨大是否涉及到退市的风险。康芝药业回复：尊敬的投资者，您好！根据《深圳证券交易所创业板股票上市规则》及相关法律法规，公司目前未触及财务类退市风险警示情形。具体情况请以公司公告为准，敬请投资者注意投资风险。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091500035222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300086","BK0048","BK0042","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662797514","title":"图解康芝药业中报：第二季度单季净利润同比增长52.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662797514","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662797514?lang=zh_cn&edition=full","pubTime":"2026-08-26 18:04","pubTimestamp":1787738676,"startTime":"0","endTime":"0","summary":"证券之星消息，康芝药业2026年中报显示，上半年度公司主营收入1.45亿元，同比下降37.67%；归母净利润-3276.65万元，同比上升39.41%；扣非净利润-4143.07万元，同比上升26.03%；其中2026年第二季度，公司单季度主营收入4831.4万元，同比下降59.75%；单季度归母净利润-2101.67万元，同比上升52.65%；单季度扣非净利润-2953.52万元，同比上升34.79%；负债率48.14%，财务费用723.6万元，毛利率54.73%。财报数据概要请见下图:本文数据来源于康芝药业2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600041241.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300086"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662779270","title":"康芝药业（300086）披露2026年半年度报告，8月26日股价下跌0.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662779270","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662779270?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:55","pubTimestamp":1787738149,"startTime":"0","endTime":"0","summary":"截至2026年8月26日收盘，康芝药业报收于6.74元，较前一交易日下跌0.44%，最新总市值为30.68亿元。该股当日开盘6.8元，最高6.88元，最低6.66元，成交额达9899.38万元，换手率为3.32%。近日，康芝药业披露2026年半年度报告。经营活动产生的现金流量净额为-11,243,259.81元，同比减少116.94%。本报告期末总资产为1,711,646,398.67元，较上年度末下降4.43%；归属于上市公司股东的净资产为866,910,179.75元，较上年度末下降3.65%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600040879.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0048","BK0239","300086","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662796864","title":"康芝药业(300086.SZ)发布上半年业绩，归母净亏损3276.65万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662796864","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662796864?lang=zh_cn&edition=full","pubTime":"2026-08-26 16:17","pubTimestamp":1787732246,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康芝药业 发布2026年半年度报告，报告期内，公司实现营业收入1.45亿元，同比下降37.67%。归属于上市公司股东净亏损3276.65万元，归属于上市公司股东的扣除非经常性损益净亏损4143.07万元。报告期内，医药板块实现营收1.26亿元，毛利率60.10%,同比提升3.48%;其中儿童药作为核心业务支柱，实现营收9,385.80 万元，毛利率 66.95%，同比提升 4.72%，盈利贡献稳定。报告期内销售费用同比下降 54.32%，前期营销投入效能显著提升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1485937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"康芝药业(300086.SZ)发布上半年业绩，归母净亏损3276.65万元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0042","300086","BK0239","BK0048","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659916920","title":"股市必读：康芝药业（300086）8月13日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2659916920","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659916920?lang=zh_cn&edition=full","pubTime":"2026-08-14 01:30","pubTimestamp":1786642232,"startTime":"0","endTime":"0","summary":"截至2026年8月13日收盘，康芝药业报收于6.97元，上涨1.6%，换手率7.13%，成交量31.4万手，成交额2.2亿元。董秘最新回复投资者： 公司作为海南头部企业，国家大力开展海南免税区，公司是否利用好了国家政策为企业发展国家兴盛做出努力。目前公司产品以内销为主，目前相关政策对公司影响较少。交易信息汇总资金流向8月13日主力资金净流入702.83万元，占总成交额3.2%；游资资金净流入1166.46万元，占总成交额5.31%；散户资金净流出1869.29万元，占总成交额8.51%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400000977.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0048","BK0239","BK0070","300086"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659524041","title":"康芝药业：目前公司产品以内销为主","url":"https://stock-news.laohu8.com/highlight/detail?id=2659524041","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659524041?lang=zh_cn&edition=full","pubTime":"2026-08-13 20:48","pubTimestamp":1786625313,"startTime":"0","endTime":"0","summary":"证券之星消息，康芝药业(300086)08月13日在投资者关系平台上答复投资者关心的问题。投资者提问：公司作为海南头部企业，国家大力开展海南免税区，公司是否利用好了国家政策为企业发展国家兴盛做出努力。康芝药业回复：尊敬的投资者，您好！目前公司产品以内销为主，目前相关政策对公司影响较少。敬请投资者理性判断、审慎决策，注意投资风险。感谢您的理解与支持！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300037332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0239","BK0048","300086","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653207880","title":"股市必读：康芝药业（300086）7月21日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2653207880","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653207880?lang=zh_cn&edition=full","pubTime":"2026-07-22 02:13","pubTimestamp":1784657583,"startTime":"0","endTime":"0","summary":"截至2026年7月21日收盘，康芝药业报收于5.94元，下跌2.3%，换手率7.96%，成交量35.07万手，成交额2.02亿元。董秘最新回复投资者： 请问公司是否有消毒剂产品？公司目前未生产销售消毒剂产品。交易信息汇总资金流向7月21日主力资金净流入309.5万元，占总成交额0.0%；游资资金净流入728.19万元，占总成交额0.0%；散户资金净流出1037.69万元，占总成交额0.0%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200002716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0048","300086","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653270910","title":"康芝药业：公司目前未生产销售消毒剂产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2653270910","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653270910?lang=zh_cn&edition=full","pubTime":"2026-07-21 20:52","pubTimestamp":1784638371,"startTime":"0","endTime":"0","summary":"证券之星消息，康芝药业(300086)07月21日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司是否有消毒剂产品？康芝药业回复：您好，感谢您对公司的关注！公司目前未生产销售消毒剂产品。公司全资子公司中山爱护日用品有限公司有相关抑菌产品，如泡泡型抑菌洗手液，可满足日常手部抑菌、清洁使用需求。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100042381.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300086","BK0070","BK0042","BK0048","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648734665","title":"创新药概念延续强势 海南海药8天6板 康芝药业涨超15%_手机新浪网","url":"https://stock-news.laohu8.com/highlight/detail?id=2648734665","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648734665?lang=zh_cn&edition=full","pubTime":"2026-07-02 10:23","pubTimestamp":1782958994,"startTime":"0","endTime":"0","summary":"　　7月2日消息，创新药概念延续强势，海南海药8天6板，康芝药业涨超15%，热景生物涨超10%，京新药业一字涨停，石药景峰涨停。　　消息面上，国家医保局近日公示了2026年药品目录调整初审结果。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202607/02/20260702457665.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202607/02/20260702457665.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangceping/20260702/32296919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","BK0048","06978","BK1574","SINA","BK0060","BK0188","BK0146","BK0239","BK0070","159992","BK0042","300086","000566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645075333","title":"康芝药业：2026年6月25日召开2025年度股东会","url":"https://stock-news.laohu8.com/highlight/detail?id=2645075333","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645075333?lang=zh_cn&edition=full","pubTime":"2026-06-22 22:03","pubTimestamp":1782136980,"startTime":"0","endTime":"0","summary":"证券日报网讯 6月22日，康芝药业（维权）发布公告称，公司将于2026年6月25日召开2025年度股东会。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-06-22/doc-inieiatp9154609.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-06-22/doc-inieiatp9154609.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0070","300086","BK0239","BK0048","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645960260","title":"每周股票复盘：康芝药业（300086）产品中选中成药集采至2028年底","url":"https://stock-news.laohu8.com/highlight/detail?id=2645960260","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645960260?lang=zh_cn&edition=full","pubTime":"2026-06-21 03:47","pubTimestamp":1781984829,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，康芝药业报收于6.05元，较上周的6.21元下跌2.58%。本周，康芝药业6月15日盘中最高价报6.36元。康芝药业当前最新总市值27.54亿元，在化学制药板块市值排名132/150，在两市A股市值排名4531/5206。本周关注点公司公告汇总：感冒清热颗粒中选全国中成药集采，采购周期至2028年12月31日。目前正式采购合同尚未签署，后续协议签订及执行存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062100001313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300086","BK0048","BK0042","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644770231","title":"康芝药业最新公告：感冒清热颗粒中选全国中成药集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2644770231","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644770231?lang=zh_cn&edition=full","pubTime":"2026-06-18 18:09","pubTimestamp":1781777379,"startTime":"0","endTime":"0","summary":"康芝药业(300086.SZ)公告称，公司产品感冒清热颗粒成功中选全国中成药采购联盟集中带量采购，采购周期至2028年12月31日。此举有望提升该产品市场占有率，强化公司在感冒类用药领域的竞争力，但正式合同尚未签署，具体影响存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800032495.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300086","BK0048","BK0070","BK0042","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638597209","title":"康芝药业(300086.SZ)：注射用头孢他啶他唑巴坦钠(3:1)临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2638597209","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638597209?lang=zh_cn&edition=full","pubTime":"2026-05-26 17:11","pubTimestamp":1779786707,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康芝药业 发布公告，近日，公司申报的“注射用头孢他啶他唑巴坦钠(3:1)”获得国家药品监督管理局核准签发的《药物临床试验批准通知书》。本次获得注射用头孢他啶他唑巴坦钠(3:1)增加儿童适用人群及用法用量的临床试验申请的《药物临床试验批准通知书》是公司在药品研发领域的阶段性成果，对公司短期的财务状况、经营业绩不构成重大影响，本次临床试验批准通知书的获得不影响本产品的销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0042","BK0239","BK0048","300086","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636834355","title":"康芝药业(300086.SZ)羧甲司坦颗粒获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2636834355","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636834355?lang=zh_cn&edition=full","pubTime":"2026-05-19 17:15","pubTimestamp":1779182137,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康芝药业(300086.SZ)发布公告，公司近日收到国家药品监督管理局核准签发的羧甲司坦颗粒药品注册证书(证书编号：2026S01525)。公告显示，羧甲司坦颗粒适用于治疗支气管炎、支气管哮喘等疾病引起的痰液粘稠、咳出困难者。公司的羧甲司坦颗粒是以2010年在日本获批上市日本杏林制药株式会社生产的羧甲司坦干糖浆剂(国家药典委员会命名为颗粒剂)为参比制剂，进行研发的。根据米内网数据：2025年国内羧甲司坦全剂型(含颗粒、口服溶液、片剂等)市场销售额约12.1亿元;其中颗粒剂占比约1.38%，对应销售额约1700万元。目前国内羧甲司坦颗粒已批准上市的厂家共有5家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康芝药业(300086.SZ)羧甲司坦颗粒获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300086","BK0048","BK0042","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634842214","title":"康芝药业：公司累计收到宏氏投资支付的履约准备金11,300万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2634842214","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2634842214?lang=zh_cn&edition=full","pubTime":"2026-05-12 20:52","pubTimestamp":1778590374,"startTime":"0","endTime":"0","summary":"证券之星消息，康芝药业05月12日在投资者关系平台上答复投资者关心的问题。针对控股股东宏氏投资的履约进展，公司已采取相关措施，具体情况如下：1.资金到账情况：公司已与宏氏投资、华夏银行开立三方共管账户。截至目前，公司累计收到宏氏投资支付的履约准备金11,300万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200038160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0048","BK0042","BK0070","300086","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634259494","title":"股市必读：康芝药业（300086）5月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2634259494","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2634259494?lang=zh_cn&edition=full","pubTime":"2026-05-11 02:08","pubTimestamp":1778436494,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，康芝药业报收于7.62元，上涨0.0%，换手率7.23%，成交量31.87万手，成交额2.47亿元。董秘最新回复投资者： 董秘你好，我在股吧看到大家讨论公司年报，关于经营质量与财务规范有一些疑问，因此想请教：① 公司经营现金流大幅改善主要来自控股股东履约款，当前主营业务的真实回款与造血能力是否已有实质改善？烦请说明，谢谢董秘： 尊敬的投资者，您好！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100001040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0070","BK0048","300086","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632060876","title":"每周股票复盘：康芝药业（300086）Q1净利降21.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632060876","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2632060876?lang=zh_cn&edition=full","pubTime":"2026-05-03 08:51","pubTimestamp":1777769469,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，康芝药业报收于7.4元，较上周的7.0元上涨5.71%。本周，康芝药业4月30日盘中最高价报7.49元。股本股东变化股东户数变动截至2026年3月31日，康芝药业股东户数为4.59万户，较2025年12月31日减少1.61万户，减幅26.0%。业绩披露要点财务报告康芝药业2026年一季报显示，一季度主营收入9657.38万元，同比下降14.09%；归母净利润-1174.97万元，同比下降21.24%；扣非净利润-1189.55万元，同比下降11.05%；负债率47.67%，财务费用354.77万元，毛利率60.56%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300002213.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","BK0048","300086","BK0042"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794359180467,"stockEarnings":[{"period":"1week","weight":0.0297},{"period":"1month","weight":-0.1148},{"period":"3month","weight":-0.2915},{"period":"6month","weight":-0.3537},{"period":"1year","weight":-0.4612},{"period":"ytd","weight":-0.596}],"compareEarnings":[{"period":"1week","weight":0.0154},{"period":"1month","weight":-0.0393},{"period":"3month","weight":-0.0717},{"period":"6month","weight":-0.1231},{"period":"1year","weight":-0.0883},{"period":"ytd","weight":-0.0769}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"康芝药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"41455人(较上一季度减少3.20%)","perCapita":"10630股","listingDate":"2010-05-26","address":"海南省海口市秀英区国家高新技术产业开发区药谷工业园药谷三路6号","registeredCapital":"45512万元","survey":"　　康芝药业股份有限公司的主营业务是儿童药、母婴健康用品的研发生产与销售。公司的主要产品是儿童药、成人药、母婴健康用品。","listedPrice":60},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康芝药业(300086)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康芝药业(300086)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康芝药业,300086,康芝药业股票,康芝药业股票老虎,康芝药业股票老虎国际,康芝药业行情,康芝药业股票行情,康芝药业股价,康芝药业股市,康芝药业股票价格,康芝药业股票交易,康芝药业股票购买,康芝药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康芝药业(300086)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康芝药业(300086)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}